Does low-dose aspirin (75–100 mg daily) prevent gastric cancer?

Low-Dose Aspirin Does NOT Prevent Gastric Cancer in the General Population

Low-dose aspirin (75-100 mg daily) should not be used for the primary prevention of gastric cancer in average-risk individuals. While emerging research suggests a potential protective effect, current guidelines do not support aspirin use specifically for gastric cancer prevention, and the evidence remains insufficient to justify its use for this indication alone.

Evidence-Based Rationale

Guideline Consensus: No Recommendation for Gastric Cancer Prevention

The most authoritative guidelines do not endorse aspirin for gastric cancer prevention:

• Colorectal cancer only: The 2021 AGA guidelines 1 and 2016 USPSTF recommendations 2 support aspirin for colorectal cancer (CRC) prevention in select populations, but make no mention of gastric cancer prevention as an indication.

• No gastric cancer indication: The 2019 British Society of Gastroenterology guidelines 3 acknowledge that aspirin and NSAIDs may reduce gastric cancer risk (RR 0.7 and 0.86 respectively), but explicitly state that "further work is undoubtedly required" and that any benefit "must be weighed against the known GI side effects."

• NCCN 2024 position: The most recent NCCN guidelines 4 concluded that "the evidence is inadequate that low-dose aspirin use reduces CRC incidence or mortality" and made no recommendations for gastric cancer prevention.

The Bleeding Risk Outweighs Uncertain Benefits

Aspirin increases gastrointestinal bleeding risk significantly 1, 5:

• Major GI bleeding: OR 1.59 (95% CI 1.32-1.91)
• Risk is even higher in adults >70 years
• The FDA label 5 explicitly warns about stomach bleeding risk, particularly in those ≥60 years, with history of ulcers, or taking blood thinners

For gastric cancer specifically, this creates a paradox: you're using a medication that causes gastric bleeding to potentially prevent gastric cancer—a questionable risk-benefit trade-off without strong evidence.

What the Research Actually Shows

Mixed and Insufficient Evidence

The research evidence is inconsistent and not strong enough to change practice:

Positive associations (but with limitations):

• A 2025 meta-analysis 6 showed RR 0.73 (95% CI 0.57-0.94) for highest vs. lowest aspirin dose, with stronger effects in Asian populations
• A 2024 Korean study 7 found reduced risk only in those with family history of gastric cancer (aHR 0.80), not in average-risk individuals
• A 2020 UK study 8 reported OR 0.46 for gastric cancer, but this was observational data with potential confounding

Critical limitations:

• Most positive studies are from high-incidence regions (Asia) and may not generalize to other populations
• A 2010 meta-analysis 9 found no overall association (OR 0.80,95% CI 0.54-1.19)
• Benefits require >3-10 years of continuous use 10, 11
• The protective effect appears limited to non-cardia gastric cancer 9

Clinical Algorithm: When to Consider Aspirin

Aspirin should only be prescribed when there is a clear cardiovascular indication 12:

1. Age 40-59 years with ≥10% 10-year CVD risk: Consider aspirin (Class IIb recommendation)

   • Use the ACC/AHA ASCVD Risk Estimator
   • Ensure patient is not at high bleeding risk
   • Any gastric cancer risk reduction is a potential secondary benefit, not the primary indication

2. Age 60-69 years: Individualize based on CVD risk vs. bleeding risk (Class IIb, but weaker)

   • Higher bleeding risk makes this less favorable

3. Age ≥70 years: Do NOT initiate aspirin for primary prevention (Class III: Harm) 12

4. Established cardiovascular disease: Aspirin 75-100 mg daily is indicated 13

Special Consideration: Family History of Gastric Cancer

In patients with a first-degree relative with gastric cancer 7:

• Low-dose aspirin may provide additional benefit (aHR 0.80)
• However, H. pylori eradication remains the primary prevention strategy 14
• Consider aspirin only if cardiovascular indications also exist

What Actually Prevents Gastric Cancer

Focus on evidence-based prevention strategies 14, 3:

1. H. pylori eradication (Grade A recommendation):

   • Most important modifiable risk factor
   • Reduces gastric cancer risk before development of atrophic gastritis
   • Test and treat in high-risk individuals

2. Endoscopic surveillance in high-risk groups:

   • Those with extensive atrophic gastritis or intestinal metaplasia
   • Family history of gastric cancer
   • Previous gastric adenoma or early cancer resection

3. Lifestyle modifications:

   • Smoking cessation
   • Reduce salt and processed meat intake
   • Increase fresh fruit and vegetable consumption

Common Pitfalls to Avoid

• Don't prescribe aspirin solely for gastric cancer prevention: The evidence is insufficient and bleeding risks are real
• Don't ignore H. pylori: This is the proven, guideline-supported intervention
• Don't assume colorectal cancer data applies to gastric cancer: These are different disease processes with different evidence bases
• Don't forget age-related bleeding risk: The risk-benefit ratio worsens significantly after age 60-70

If a patient is already taking aspirin for cardiovascular reasons, they may derive some gastric cancer protection as a secondary benefit—but this should not change gastric cancer screening recommendations 15.